LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

High Levels of Biomarker Protein Indicate Poor Prognosis for Cancer Patients

By LabMedica International staff writers
Posted on 15 Mar 2017
Print article
Image: A scanning electron micrograph (SEM) of ovarian cancer cells (Photo courtesy of Steve Gschmeissner / SPL).
Image: A scanning electron micrograph (SEM) of ovarian cancer cells (Photo courtesy of Steve Gschmeissner / SPL).
The surface biomarker protein CD151 has been linked to a poor prognosis for patients suffering from high-grade serous ovarian cancer (HGSC), the most common and lethal subtype of the disease.

CD151 a member of the transmembrane four superfamily, also known as the tetraspanin family. These are mainly cell-surface proteins characterized by the presence of four hydrophobic domains. These proteins mediate signal transduction events that play a role in the regulation of cell development, activation, growth, and motility. CD151 is involved in cellular processes including cell adhesion and may regulate integrin trafficking and/or function. This protein enhances cell motility, invasion, and metastasis of cancer cells.

Investigators at University Health Network performed genome-wide RNAi screens and comprehensive expression analysis of cell-surface markers on a panel of cell lines derived from 40 HGSC patient tumor samples to identify genes that were critical to their survival.

The investigators found that CD151 contributed to survival of a subset of HGSC cell lines associated with a transcriptional program mediated by the proteins ZEB1 (Zinc finger E-box-binding homeobox 1) and ZEB2 (Zinc finger E-box-binding homeobox 2) and supported the growth of HGSC tumors.

Following up, the investigators analyzed tissue samples from a group of approximately 1,000 HGSC patients and found that high levels of CD151 correlated with poor prognosis.

"Ovarian cancer is many diseases," said first author Dr. Mauricio Medrano, postdoctoral researcher at University Health Network. "By identifying CD151 and its underlying role in cancer cell survival, we hope to develop a therapy to target it. As a marker for poor prognosis, with further research, there is the potential to develop a clinical screening tool to help personalize cancer treatment for patients. For the scientific community our study provides a lot of new information about other possible targets, not only CD151 that could be important and can provide new ideas for how to target ovarian cancer."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more